30 results on '"Akerley W"'
Search Results
2. P1.09B.04 Impact of BMI on TTFields in Patients with Mnsclc: Post-hoc Analysis from the Phase 3 LUNAR Study and Simulation Model Data
3. OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study
4. P2.07-06 Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics
5. P24.01 Turnaround Time and Variant Prevalence of a Blood-based KRAS Test in Patients With NSCLC
6. P63.11 Real-World Survival Outcomes of Patients with Limited Stage Small Cell Lung Cancer (LS-SCLC) by Choice of Platinum Chemotherapy
7. P01.07 Real World Outcomes of Advanced Non-Small Cell Lung Cancer (NSCLC) With Attention to Carboplatin Area Under the Curve (AUC) = 5 Versus 6
8. OA09.05 Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Physician’s Choice of First-line Platinum Chemotherapy
9. P47.07 KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC
10. P27.01 Patterns of Care and Outcomes in Clinical T3N0M0 Non-Small Cell Lung Cancer Without Invasion of Other Structures
11. Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: A phase II trial of Cancer and Leukemia Group B
12. Preoperative Chemoradiation Coupled with Aggressive Resection as Needed Ensures Near Total Control in Advanced Head and Neck Cancer
13. P1.01-35 Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers
14. MA14.09 Real-World Survival of Relapsed Compared to De-Novo Stage IV Diagnosis of Advanced Non-Small Cell Lung Cancer
15. PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers
16. P89.05 Management of Patients with EGFR and ALK-Mutated Advanced Non-Small Cell Lung Cancer Post-TKI Therapy – A Real-World Survival Analysis
17. FP05.01 Real-World Survival Outcomes of Patients with Malignant Pleural Mesothelioma by Choice of Second-line Therapy
18. P15.02 Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC
19. OA02.02 Long Term Follow up of Ipilimumab and Targeted Therapy for Metastatic EGFR/ALK Lung Cancer
20. MA03.10 Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer
21. OA12.06 Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure
22. P3.01-13 Prognosis of Non-driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC)
23. P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)
24. Safety of Bevacizumab Therapy in Subjects with Brain Metastases due to Non–Small-Cell Lung Cancer (NSCLC)
25. Response to chemotherapy as a predictor of survival in advanced non-small cell lung cancer (NSCLC): Review of the Southwest Oncology Group (SWOG) database
26. Role of paclitaxel in combined modality therapy for locally advanced non-small cell lung cancer (NSCLC): Multiinstitutional trials exploring sequential phase II studies of paclitaxel +/- carboplatin and radiation therapy (+/-hyperfractionation: HFXRT)
27. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions
28. 593Concurrent paclitaxel, carboplatin and radiation therapy followed by adjuvant paclitaxel/carboplatin for stage III non-small cell lung cancer
29. 593Concurrent paclitaxel, carboplatin and radiation therapy followed by adjuvant paclitaxel/carboplatin for stage III non-small cell lung cancer
30. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.